Acute Myeloid Leukemia (AML)

2025 EHA/ASCO Update: MDS and AML

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
In this webinar, Dr. Jan Bewersdorf discusses the latest research presented at EHA and ASCO on MDS and AML. This is an advanced presentation.

Jose C. Martinez, MD, PhD

Institution
University of North Carolina at Chapel Hill School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
I am a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis and myeloid cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). My clinical and research interests focus on RNA regulation in hematologic malignancies. Specifically, I investigate how mutations in splicing factors affect RNA processing and contribute to disease progression. These genetic mutations can occur at any stage of life, leading to complex disorders that are often challenging to diagnose and treat. In the laboratory, we utilize advanced genomic technologies

Lacey Williams, MD

Institution
University of North Carolina School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Dr. Lacey Williams specializes in the care of patients with acute leukemias and myeloid malignancies, with interests in germline syndromes and improving outcomes for minority populations. She chose the field of oncology for the combination of close patient relationships and opportunities for scientific advances in the field. She aims to support patients during their treatment journey with the most helpful information and clinical resources

Curing the Incurable: TP53 Mutated Myeloid Neoplasms

Original Publication Date
Article Source
External Web Content
Abstract The TP53 gene ensures genetic fidelity by regulating cell cycle kinetics and apoptosis. In myeloid neoplasms, TP53 mutation is witnessed in 13% of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Alterations in TP53 or its respective protein is…

Clinical Study on Targeted Drug Expands Treatment Options for Myelodysplastic Syndrome

Original Publication Date
Article Source
External Web Content
Their research led to the 2022 approval of olutasidenib for certain patients with IDH1-mutant AML, which occurs in about 10% of AML. After that success, Dr. Watts and his team began to focus closely on testing the drug in MDS, a related condition that often progresses to AML. IDH…

Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML

Original Publication Date
Article Source
External Web Content
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This combination may be an opportune bridge to transplantation, according to David A. Sallman, MD, of the…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.